Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302395 | 0.85 | PTPN1 (0.44) | PTPN1RAB9ATDP1ALDH1A1ERN1 | |
| SCHEMBL4033691 | 0.82 | CYP19A1 (0.43) | PTPN1RAB9ATDP1ALDH1A1ERN1 | |
| SCHEMBL4030812 | 0.81 | ERN1 (0.58) | PTPN1NPC1RAB9ATDP1ALDH1A1 | |
| SCHEMBL1751525 | 0.80 | ALDH1A1 (0.48) | NPC1RAB9ATDP1ALDH1A1EGFR | |
| SCHEMBL1750895 | 0.79 | HTT (0.43) | NPC1RAB9ATDP1ALDH1A1EGFR | |
| Hydrochloric Acid SCHEMBL4026672 | 0.79 | ALDH1A1 (0.47) | NPC1RAB9ATDP1ALDH1A1EGFR | |
| SCHEMBL13693816 | 0.77 | GAK (0.38) | NPC1RAB9AALDH1A1EGFRMAPT | |
| SCHEMBL1647979 | 0.77 | MAOA (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3663573 | 0.76 | MAOA (0.52) | NPC1RAB9ATDP1ALDH1A1EGFR | |
| SCHEMBL4236677 | 0.75 | EGFR (0.39) | NPC1RAB9ATDP1ALDH1A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225205-B1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2013-01-02 | — | — | EP | disclosed |
| US-7968724-B2 | Ester derivatives as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| EP-2225205-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009077068-A9 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2009-08-20 | — | — | WO | disclosed |
| US-20090182143-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090170903-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-07-02 | — | — | US | disclosed |
| WO-2009077068-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070913-A1 | Ester derivatives as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-06-17 | — | — | EP | disclosed |
| EP-1620429-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS SA (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-7393846-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-07-01 | — | — | US | disclosed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | disclosed |
| US-7223789-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-29 | — | — | US | disclosed |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| US-20070105854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| EP-1620429-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Glenmark Pharmaceuticals S.A. (CH) | 2006-02-01 | — | — | EP | disclosed |
| EP-1554262-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Glenmark Pharmaceuticals Limited (IN) | 2005-07-20 | — | — | EP | disclosed |
| US-20050027129-A1 | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS, INC. USA | 2005-02-03 | — | — | US | disclosed |
| WO-2004089940-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004037805-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182143-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | PTPN1 1328/4885NPC1 2455/4885RAB9A 1467/4885 |
| US-20050027129-A1 | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | PDE4A, PDE4B, PDE12 | PTPN1 1328/4885NPC1 2455/4885RAB9A 1467/4885 |
| US-20070105854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | PTPN1 1328/4885NPC1 2455/4885RAB9A 1467/4885 |
| US-20090170903-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE5A | PTPN1 2310/4885NPC1 2240/4885RAB9A 1772/4885 |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | PTPN1 1328/4885NPC1 2455/4885RAB9A 1467/4885 |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | LTC4S, TSLP, GPR119 | PTPN1 3734/4885NPC1 853/4885RAB9A 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.